Science

Apr 18, 2025, 16:18

Myeloma Paper of the Day, April 18th, suggested by Robert Orlowski

Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: German multicenter analysis of talquetamab in 138 patients with RRM finds ORR 65%, median PFS 6.4 months; prior BTCE exposure, ISS stage III, and extraosseous and penta-drug refractory disease associated with unfavorable outcomes.”

“A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma”

Authors: Jan Frenking, Christine Riedhammer, Raphael Teipel, Florian Bassermann, Britta Besemer, Ralph Wäsch, Romans Zukovs, Mathias Hänel, Leo Rasche, Marc Raab et al.

More posts featuring Robert Orlowski.

Britta Besemer cancer Christine Riedhammer Florian Bassermann Jan Frenking Leo Rasche Marc Raab Mathias Hänel multiple myeloma Myeloma Paper of the Day OncoDaily Oncology Ralph Wäsch Raphael Teipel relapsed/refractory multiple myeloma Robert Orlowski Romans Zukovs RRMM Talquetamab

Top 5 AI Tools for Radiation Oncologists: What Clinicians Need to Know

FDA Grants Accelerated Approval to Sunvozertinib for EGFR Exon 20 Insertion Mutations in NSCLC

Uhm Jung-hwa: Korea’s Iconic ‘Madonna’ and Her Triumphant Battle Against Thyroid Cancer

Vincent Rajkumar: A Historic Day for High Risk Smoldering Myeloma

Dr. Anastasia Constantinidou Nominated for Madame Figaro Woman of the Year 2025